MedTrace Logo

Fluoxetine as a Quit Smoking AID for Depression Prone

NCT00113737 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL

Last updated 2016-02-18

No results posted yet for this study

Summary

To test whether adding fluoxetine pharmacotherapy to behavioral cessation treatment improves the depression-prone smoker's ability to quit.

Conditions

Interventions

DRUG

fluoxetine

BEHAVIORAL

cognitive behavioral therapy

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    lead NIH

Principal Investigators

  • Bonnie Spring · U.S. Dept/Vets Affairs Med Ctr.

Study Design

Purpose
PREVENTION
Masking
DOUBLE

Eligibility

Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1998-02-28
Completion
2002-01-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00113737 on ClinicalTrials.gov